In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary ...

HHS Secretary Robert F. Kennedy Jr. reorganized senior leadership at the department to streamline management and advance the ...

What’s been overlooked is that the FDA already has the power to fix this. Without new legislation, pilot programs, or years ...

FDA approved a simplified, once-monthly dosing schedule for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) when used in combination with Lazcluze (lazertinib) as a first-line treatment for ...

Sandy Tammisetty, VP of Veeva Services Practive Group at Conexus Solutions, spoke with Pharmaceutical Executive about where AI implementation is working for the pharma industry, and where it doesn’t ...

In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, ...

Scaling without losing local relevance requires humility, trust, and a willingness to relinquish the illusion that control ...

Disc Medicine received a Complete Response Letter (CRL) from FDA for its New Drug Application (NDA) for bitopertin as a treatment for erythropoietic protoporphyria (EPP), delaying a potential ...

Edwards Lifesciences withdrew its global anti-copycat policy, prompting European Union antitrust regulators to close an investigation that began with dawn raids back in 2023. The European Commission ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

A Partner at ZS Associates, he works across medical engagement, decision engines, omnichannel strategy, and customer data foundations. He has partnered with medical affairs teams across the US and ...

Edwards Lifesciences withdrew its global anti-copycat policy, prompting European Union antitrust regulators to close an investigation that began with dawn raids back in 2023. The European Commission ...